$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000032001714000022 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$4.489K	$4.056K	$2.524K
YoY Change	2.98%	60.7%	-99.93%
Cost Of Revenue	$3.677M	$3.825M	$2.392M
YoY Change	-13.17%	59.92%	-19.07%
Gross Profit	-$3.673M	-$3.821M	$131.8K
YoY Change	-3052.89%	-2998.88%	-83.87%
Gross Profit Margin	-81819.25%	-94215.68%	5222.78%
Selling, General & Admin	$7.446M	$8.970M	$5.802M
YoY Change	72.26%	54.61%	-9.52%
% of Gross Profit			4401.26%
Research & Development	$5.796M	$4.759M	$3.161M
YoY Change	45.92%	50.54%	62.35%
% of Gross Profit			2398.16%
Depreciation & Amortization	$550.0K	$440.0K	$550.0K
YoY Change	96.43%	-20.0%	41.03%
% of Gross Profit			417.23%
Operating Expenses	$16.92M	$17.55M	$11.36M
YoY Change	35.04%	54.59%	35.84%
Operating Profit	-$12.43M	-$13.50M	-$8.831M
YoY Change	52.14%	52.85%	17.09%
Interest Expense	$105.9K	$94.16K	$43.56K
YoY Change	60.84%	116.15%	-91.69%
% of Operating Profit
Other Income/Expense, Net	-$291.6K	-$283.7K	-$32.95K
YoY Change	3594.49%	760.92%	-92.45%
Pretax Income	-$12.72M	-$13.78M	-$8.864M
YoY Change	55.56%	55.48%	11.09%
Income Tax	$47.39K	$47.41K	$0.00
% Of Pretax Income
Net Earnings	-$12.61K	-$13.68K	-$8.801K
YoY Change	47.0%	55.46%	-99.91%
Net Earnings / Revenue	-280.8%	-337.33%	-348.69%
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.978M	-$4.868M	-$5.269M
COMMON SHARES
Basic Shares Outstanding	34.01M shares	28.58M shares	168.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.79M	$41.40M	$9.300M
YoY Change	129.84%	345.16%	-57.34%
Cash & Equivalents	$32.87M	$41.36M	$9.254M
Short-Term Investments	$920.8K
Other Short-Term Assets	$4.500M	$3.300M	$2.500M
YoY Change	350.0%	32.0%	-10.71%
Inventory	$2.033M	$1.476M	$1.542M
Prepaid Expenses
Receivables	$2.510M	$1.888M	$886.2K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$40.85M	$46.56M	$12.68M
YoY Change	148.37%	267.26%	-76.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.64M	$13.79M	$10.79M
YoY Change	43.83%	27.76%	-77.19%
Goodwill	$14.09M	$11.12M	$11.12M
YoY Change	26.75%	0.0%	-43.47%
Intangibles	$49.36M	$13.72M	$14.33M
YoY Change	248.16%	-4.22%	-60.5%
Long-Term Investments
YoY Change
Other Assets	$1.460M	$1.205M	$979.1K
YoY Change	47.33%	23.05%	-84.12%
Total Long-Term Assets	$92.54M	$39.84M	$37.22M
YoY Change	149.03%	7.03%	-67.44%
TOTAL ASSETS
Total Short-Term Assets	$40.85M	$46.56M	$12.68M
Total Long-Term Assets	$92.54M	$39.84M	$37.22M
Total Assets	$133.4M	$86.39M	$49.90M
YoY Change	148.83%	73.14%	-70.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.481M	$3.296M	$2.191M
YoY Change	127.38%	50.41%	-88.7%
Accrued Expenses	$2.587M	$2.382M	$1.683M
YoY Change	30.12%	41.51%	-50.94%
Deferred Revenue
YoY Change
Short-Term Debt	$200.0K	$200.0K	$3.400M
YoY Change	-93.94%	-94.12%	-82.47%
Long-Term Debt Due	$800.0K	$800.0K	$100.0K
YoY Change	166.67%	700.0%	-66.67%
Total Short-Term Liabilities	$11.91M	$8.786M	$9.228M
YoY Change	42.07%	-4.79%	-80.42%
LONG-TERM LIABILITIES
Long-Term Debt	$3.900M	$3.800M	$100.0K
YoY Change	1850.0%	3700.0%	-97.62%
Other Long-Term Liabilities	$635.0K	$635.0K	$275.4K
YoY Change	65.75%	130.62%	-98.9%
Total Long-Term Liabilities	$635.0K	$27.33M	$11.66M
YoY Change	-94.81%	134.27%	-65.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.91M	$8.786M	$9.228M
Total Long-Term Liabilities	$635.0K	$27.33M	$11.66M
Total Liabilities	$56.10M	$36.11M	$20.89M
YoY Change	172.09%	72.85%	-74.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$262.7M	-$250.1M	-$206.2M
YoY Change	22.3%	21.27%	35.16%
Common Stock	$34.94K	$28.59K	$170.3K
YoY Change	78.41%	-83.21%	31.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$705.7K	$705.7K	$665.6K
YoY Change	6.03%	6.03%
Treasury Stock Shares
Shareholders Equity	$78.04M	$59.64M	$29.42M
YoY Change
Total Liabilities & Shareholders Equity	$133.4M	$86.39M	$49.90M
YoY Change	148.83%	73.14%	-70.17%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$12.61K	-$13.68K	-$8.801K
YoY Change	47.0%	55.46%	-99.91%
Depreciation, Depletion And Amortization	$550.0K	$440.0K	$550.0K
YoY Change	96.43%	-20.0%	41.03%
Cash From Operating Activities	-$11.26M	-$11.25M	-$7.136M
YoY Change	87.98%	57.71%	-438.76%
INVESTING ACTIVITIES
Capital Expenditures	-$1.200M	$1.240M	$53.57K
YoY Change	445.45%	2213.95%	-59.41%
Acquisitions
YoY Change
Other Investing Activities	-$870.0K		$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$2.070M	-$1.240M	-$53.57K
YoY Change	840.91%	2213.95%	-51.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.830M	$7.719M	$2.705M
YoY Change	-58.61%	185.32%	-62.35%
NET CHANGE
Cash From Operating Activities	-11.26M	-$11.25M	-$7.136M
Cash From Investing Activities	-2.070M	-$1.240M	-$53.57K
Cash From Financing Activities	4.830M	$7.719M	$2.705M
Net Change In Cash	-8.500M	-$4.774M	-$4.484M
YoY Change	-255.68%	6.47%	-148.83%
FREE CASH FLOW
Cash From Operating Activities	-$11.26M	-$11.25M	-$7.136M
Capital Expenditures	-$1.200M	$1.240M	$53.57K
Free Cash Flow	-$10.06M	-$12.49M	-$7.189M
YoY Change	74.35%	73.77%	-464.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3296078	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3354908	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1887558	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1860835	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4018026	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2381625	USD
CY2013Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	4018.0	USD
CY2014Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2381.6	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	544.8	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	775.4	USD
CY2014Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	200.0	USD
CY2013Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	500.0	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	310377112	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	299594525	USD
CY2013Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	6239	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2218500	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3893600	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	391829	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	390118	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151300	USD
CY2013Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151300	USD
CY2014Q1	us-gaap	Assets Assets	86393625	USD
CY2013Q4	us-gaap	Assets Assets	89816082	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	46556104	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	50826750	USD
CY2013Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	190000	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9640000	USD
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9450000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41359652	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46133759	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4483861	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4774107	USD
CY2014Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	700000	USD
CY2013Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	800000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28593410	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27196537	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28593410	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27196537	shares
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-63754	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8864329	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-13830084	USD
CY2014Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2013Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2013Q1	us-gaap	Cost Of Revenue CostOfRevenue	2392089	USD
CY2014Q1	us-gaap	Cost Of Revenue CostOfRevenue	3825444	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	28594	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	27197	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8800575	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13682057	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-148027	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2033116	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1816601	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	4379226	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	4426635	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	444452	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	554954	USD
CY2014Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	23175	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	23175	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2014Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	846.4	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2325.8	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	100000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1893400	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2044700	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	10849600	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	453900	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	605200	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	605200	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	605200	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	605200	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13724300	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13875600	USD
CY2013Q4	us-gaap	Goodwill Goodwill	11117770	USD
CY2014Q1	us-gaap	Goodwill Goodwill	11117770	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-63754	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-148027	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8864329	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13782675	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	47409	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25012	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-167444	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	22986	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	271149	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	192009	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	13875617	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	13724314	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	43560	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	94156	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	95700	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-47409	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	216515	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	346912	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	428549	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	205589	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	53035	USD
CY2014Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	870864	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	531164	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86393625	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89816082	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9806919	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8786218	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	27789647	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	27326673	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	93100	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	1475812	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	1270223	USD
CY2013Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2218530	USD
CY2014Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3893616	USD
CY2014Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2013Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2014Q1	us-gaap	Minority Interest MinorityInterest	-577450	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	-516040	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7719039	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2705443	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1239606	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53571	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11253540	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7135733	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13682057	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8800575	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-283707	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-32954	USD
CY2014Q1	us-gaap	Notes Payable NotesPayable	1700000	USD
CY2013Q4	us-gaap	Notes Payable NotesPayable	900000	USD
CY2014Q1	us-gaap	Notes Payable Current NotesPayableCurrent	836219	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	381097	USD
CY2012Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2012Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	11355287	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	17554543	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8831375	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13498968	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2678500	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	386900	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	682300	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	840400	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	763000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	5900	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	110600000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13790672	USD
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2014Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	559.8	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	71360	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2013Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	105881	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1275000	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-8864329	USD
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-13830084	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12844216	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	647.4	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1204765	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1151729	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	635008	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	598729	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10606	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-189551	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1239606	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53571	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1833082	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1561933	USD
CY2014Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5630625	USD
CY2013Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2730262	USD
CY2013Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	958014	USD
CY2013Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	81015	USD
CY2014Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	163192	USD
CY2013Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	43446	USD
CY2014Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	52768	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3161326	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4759083	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-236373605	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-250055662	USD
CY2013Q1	us-gaap	Revenues Revenues	2523912	USD
CY2014Q1	us-gaap	Revenues Revenues	4055575	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	0	shares
CY2013Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	177492	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	329698	shares
CY2013Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2730263	USD
CY2014Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5630625	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1127900	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2511700	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3893616	USD
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	213112	USD
CY2014Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	216005	USD
CY2014Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2967948	USD
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	3023609	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5801872	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8970016	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4473306	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1896700	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1848900	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1600900	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	3913	shares
CY2013Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2218530	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	62542475	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	59644402	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	62026435	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	59066952	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32820159	USD
CY2013Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29004265	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	705742	USD
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	705742	USD
CY2013Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	10606	USD
CY2014Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2014Q1	nbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	1661500	USD
CY2014Q1	nbs	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	1661500	USD
CY2014Q1	nbs	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	1661500	USD
CY2013Q1	nbs	Cashand Cash Equivalents Ending Balance CashandCashEquivalentsEndingBalance	9253591	USD
CY2014Q1	nbs	Cashand Cash Equivalents Ending Balance CashandCashEquivalentsEndingBalance	41359652	USD
CY2013Q4	nbs	Cashand Cash Equivalentsat Carrying Value Including Discontinued Operations Beginning Balance CashandCashEquivalentsatCarryingValueIncludingDiscontinuedOperationsBeginningBalance	46133759	USD
CY2012Q4	nbs	Cashand Cash Equivalentsat Carrying Value Including Discontinued Operations Beginning Balance CashandCashEquivalentsatCarryingValueIncludingDiscontinuedOperationsBeginningBalance	13737452	USD
CY2014Q1	nbs	Change In Warrant Liabilities ChangeInWarrantLiabilities	0	USD
CY2013Q1	nbs	Change In Warrant Liabilities ChangeInWarrantLiabilities	6239	USD
CY2014Q1	nbs	Changein Ownershipin Subsidiary ChangeinOwnershipinSubsidiary	0	USD
CY2014Q1	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	700000	USD
CY2013Q1	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	400000	USD
CY2013Q4	nbs	Common Stock Warrants Shares CommonStockWarrantsShares	4898266	shares
CY2014Q1	nbs	Common Stock Warrants Shares CommonStockWarrantsShares	4491028	shares
CY2013Q1	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-905094	USD
CY2014Q1	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-1658952	USD
CY2014Q1	nbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	5.10
CY2014Q1	nbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	70.00
CY2013Q4	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2014Q1	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2013Q1	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	0	USD
CY2014Q1	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	1711	USD
CY2014Q1	nbs	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	4491028	shares
CY2014Q1	nbs	Stock Option Exercise StockOptionExercise	12800	shares
CY2014Q1	nbs	Warrants Canceled WarrantsCanceled	59852	shares
CY2014Q1	nbs	Warrants Exercised WarrantsExercised	250000	shares
CY2014Q1	nbs	Warrants Expired WarrantsExpired	100108	shares
CY2014Q1	nbs	Warrants Granted WarrantsGranted	2722	shares
CY2013Q1	nbs	Warrants Issued During Period Value WarrantsIssuedDuringPeriodValue	14900	USD
CY2014Q1	nbs	Warrants Issued During Period Value WarrantsIssuedDuringPeriodValue	0	USD
CY2013Q1	nbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	6.35
CY2014Q1	nbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	7.62
CY2014Q1	nbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	57.76
CY2014Q1	nbs	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	15.42
CY2014Q1	nbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	12.26
CY2013Q4	nbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	16.50
CY2014Q1	nbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	15.39
CY2014Q1	nbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P2Y4M24D
CY2014Q1	nbs	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P2Y3M18D
CY2014Q1	nbs	Weighted Average Exercise Price Warrantsvestedexpectedtovest WeightedAverageExercisePriceWarrantsvestedexpectedtovest	15.39
CY2014Q1	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	28120847	shares
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	16698897	shares
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	NeoStem, Inc.
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34008862	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	dei	Entity Public Float EntityPublicFloat	92300000	USD

Files In Submission

Name	View Source	Status
0000320017-14-000022-index-headers.html	Edgar Link	pending
0000320017-14-000022-index.html	Edgar Link	pending
0000320017-14-000022.txt	Edgar Link	pending
0000320017-14-000022-xbrl.zip	Edgar Link	pending
exhibit104.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nbs-10qx20140331.htm	Edgar Link	pending
nbs-20140331.xml	Edgar Link	completed
nbs-20140331.xsd	Edgar Link	pending
nbs-20140331_cal.xml	Edgar Link	unprocessable
nbs-20140331_def.xml	Edgar Link	unprocessable
nbs-20140331_lab.xml	Edgar Link	unprocessable
nbs-20140331_pre.xml	Edgar Link	unprocessable
nbs-ex311_20140331xq1.htm	Edgar Link	pending
nbs-ex312_20140331xq1.htm	Edgar Link	pending
nbs-ex321_20140331xq1.htm	Edgar Link	pending
nbs-ex322_20140331xq1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2014 Q2 Form 10-Q Financial Statement

#000032001714000022 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2014 Q2 Form 10-Q Financial Statement

#000032001714000022 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta